CD274 [B7-H1] (human)-muIg Fusion Protein (Biotin)
Code | Size | Price |
---|
ANC-541-030-25ug | 25 ug | £572.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Hamster
Regulatory Status: RUO
Target Species: Human
Application: Enzyme-Linked Immunosorbent Assay (ELISA)
Shipping:
BI
Storage:
+4°C
Documents
Further Information
Alternate Names/Synonyms:
B7-H1; Programmed Cell Death 1 Ligand 1; PD-L1; PDCD1 Ligand 1
EClass:
32160000
Form (Short):
liquid
Formulation:
50 mM Sodium Phosphate pH 7.5, 100 mM Potassium Chloride, 150mM NaCl, 5% Glycerol, 0.2% BSA, 0.04% NaN3 (as a preservative).
Handling Advice:
Avoid freeze/thaw cycles.
Labels - Conjugates:
Biotin
Long Description:
Protein. Liquid. 50 mM Sodium Phosphate pH 7.5, 100 mM Potassium Chloride, 150mM NaCl, 5% Glycerol, 0.2% BSA, 0.04% NaN3 (as a preservative). CD274 (B7-H1; PD-L1; Programmed Death Ligand) is a member of the B7 family and is expressed on a variety of tissues including lymphoid cells. It plays an important role in regulation of T cell activation and is involved in progression of cancer, arthritis and HIV infection. CD274 binding to its receptor CD279 (PD-1) on activated T cells can decrease proliferation. Conversely, ligation of CD279 on primed T cells can stimulate IL-10 production. High levels of CD274 present in renal cell carcinoma is associated with poor prognosis. Tumor expressed CD274 can increase apoptosis of tumor specific T cells resulting in better tumor cell survival.
Package Type:
Plastic Vial
Product Description:
CD274 (B7-H1; PD-L1; Programmed Death Ligand) is a member of the B7 family and is expressed on a variety of tissues including lymphoid cells. It plays an important role in regulation of T cell activation and is involved in progression of cancer, arthritis and HIV infection. CD274 binding to its receptor CD279 (PD-1) on activated T cells can decrease proliferation. Conversely, ligation of CD279 on primed T cells can stimulate IL-10 production. High levels of CD274 present in renal cell carcinoma is associated with poor prognosis. Tumor expressed CD274 can increase apoptosis of tumor specific T cells resulting in better tumor cell survival.
Source / Host:
CHO cells
TAGs:
Fc
Transportation:
Non-hazardous
UNSPSC Category:
Other Proteins
UNSPSC Number:
12352202
Use & Stability:
Stable for at least 6 months after receipt when stored at +4°C.
Related Products
Product Name | Product Code | Supplier | anti-CD274 [B7-H1] (human), mAb (ANC6H1) | ANC-274-020 | Ancell | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
anti-CD274 [B7-H1] (human), mAb (ANC6H1) (Biotin) | ANC-274-030 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
anti-CD274 [B7-H1/PD-L1] (human), mAb (ANC6H1) (FITC) | ANC-274-040 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
anti-CD274 [B7-H1/PD-L1] (human), mAb (ANC6H1) (R-PE) | ANC-274-050 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
anti-CD274 [B7-H1] (human), mAb (ANC6H1) (preservative free) | ANC-274-820 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CD274 [B7-H1] (human)-muIg Fusion Protein | ANC-541-020 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CD274 [B7-H1] (human)-muIg Fusion Protein (preservative free) | ANC-541-820 | Ancell | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||